Rotavirus Vaccine

Su Eun Park

doi:10.5124/jkma.2008.51.2.137

J Korean Med Assoc > Volume 51(2); 2008 > Article

Park: Rotavirus Vaccine

Focused Issue of This Month

Newly Developed Vaccines and New Vaccination

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2008; 51(2): 137-143.

Published online: February 28, 2008

DOI: http://dx.doi.org/10.5124/jkma.2008.51.2.137

Rotavirus Vaccine

Su Eun Park, MD

Department of Childhood and Adolescent Medicine, Pusan National University College of Medicine, Korea. psepse@naver.com

Abstract

Rotavirus is the most common cause of severe gastroenteritis in children throughout the world. The first licensed rotavirus vaccine (RRV-TV) was withdrawn in 1999 because of its association with intussusception. Two recent large clinical trials of two new rotavirus vaccines (5-valent rotavirus vaccine and monovalent rotavirus vaccine) showed 90~95% efficacy against severe rotavirus gastroenteritis. There was no evidence of increased rates of intussusception with theses two vaccines. One of the two vaccines has been introduced into the childhood vaccination schedule in some countries. Five-valent rotavirus vaccine is licensed in Korea in June 2007. This review is focused on the efficacy, safety, and immunogenicity of 5-valent rotavirus vaccine and provides the methods of immunization of 5-valent rotavirus vaccine.

Rotavirus; Rotavirus vaccine; Intussusception

References

1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005;365:1147-1152.

2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-572.

3. Bresee JS, Hummelman E, Nelson EA, Glass RI. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis 2005;192:S. S1-S5.

4. World Health Organization. Rotavirus vaccines: WHO position Paper. Wkly Epidemiol Rec 1999;74:33-40.

5. Centers for Disease Control and Prevention (CDC). Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48:1007.

6. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lpez P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroentsritis. N Engl J Med 2006;354:11-22.

7. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.

8. Nakagomi O, Cunliffe NA. Rotavirus vaccines: entering a new stage of deployment. Curr Opin Infect Dis 2007;20:501-507.

9. Buttery JP, Kirkwood C. Rotavirus vaccines in developed countries. Curr Opin Infect Dis 2007;20:253-258.

10. Kang JH. Epidemiological profile of rotavirus infection in Korea 2006;24th Annual meeting of the European Society for Pediatric Infectious Disease. May 3-5. Basel. Switzerland.

11. Jee YM. Epidemiological study of viral gastroenteritis in Korea. J Korean Pediatr Infect Dis 2003;10:26-36.

12. Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 2000;19:S103-S105.

13. CDC. Prevention of rotavirus gastroenteritis among infants and children. MMWR 2006;55(RR-12.

14. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007;119:171-182.

15. Clark HF, Offit PA, Glass RI, Ward RL. In: Plotkin SA, Orenstein WA, editor. Rotavirus vaccines. Vaccines 2004;4th ed. Philadelphia: WB Saunders. 1327-1345.

16. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW, Wharton M, Livengood JR. Rotavirus Intussusception Investigation Team. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-572.

17. Clark HF, Offit PA, Plotkin SA, Heaton PM. The new pentavalent rotavirus vaccine composed of Bovine (strain WC3)-human rotavirus reassortants. Pediatr Infect Dis J 2006;25:577-583.

18. Offit PA, Clark HF. Rotateq: A pentavalent bovine-human reassortant rotavirus vaccine. Pediatr Ann 2006;35:29-34.

19. Kim DS, Lee TJ, Kang JH, Kim JH, Lee JH, Ma SH, Kim SY, Kim HM, Shin SM. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J 2008;28:Epub ahead of print.

20. Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ. REST Study Team. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007;26:1099-1104.

21. Centers for Disease Control and Prevention (CDC). Postmarketing monitoring of intussusception after RotaTeq vaccination-United States, February 1, 2006-February 15, 2007. MMWR Morb Mortal Wkly Rep 2007;56:218-222.